Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Biochemistry
Exendin‐4 Enhances Osteogenic Differentiation Of Adipose Tissue Mesenchymal Stem Cells Through The Receptor Activator Of Nuclear Factor‐Kappa B And Osteoprotegerin Signaling Pathway, Sarah A. Habib, Mohamed M. Kamal, Shohda A. El-Maraghy, Mahmoud A. Senousy
Exendin‐4 Enhances Osteogenic Differentiation Of Adipose Tissue Mesenchymal Stem Cells Through The Receptor Activator Of Nuclear Factor‐Kappa B And Osteoprotegerin Signaling Pathway, Sarah A. Habib, Mohamed M. Kamal, Shohda A. El-Maraghy, Mahmoud A. Senousy
Pharmacy
The capability of mesenchymal stem cells (MSCs) to repair bone damage and defects has long been investigated. The receptor activator of nuclear factorkappa B (RANK), its ligand (RANKL) and the decoy receptor osteoprotegerin (OPG) axis is crucial to keep the equilibrium between osteoblastic and osteoclastic activity. Exendin‐4 utilization increased bone formation and enhanced bone integrity. This study aimed to investigate the mentioned axis and determine the effect of exendin‐4 upon adipose mesenchymal stem cells (Ad‐MSCs) osteogenic differentiation. Ad‐MSCs were isolated from rat epididymal fat, followed by characterization and then differentiation into osteocytes both in the presence or absence of exendin‐4. …
Exosomal-Long Non-Coding Rnas Journey In Colorectal Cancer: Evil And Goodness Faces Of Key Players, Nehal I. Rizk, Ahmed I. Abulsoud, Mohamed M. Kamal, Dina H. Kassem, Nadia M. Hamdy
Exosomal-Long Non-Coding Rnas Journey In Colorectal Cancer: Evil And Goodness Faces Of Key Players, Nehal I. Rizk, Ahmed I. Abulsoud, Mohamed M. Kamal, Dina H. Kassem, Nadia M. Hamdy
Pharmacy
Exosomes are nano-vesicles (NVs) secreted by cells and take part in cell-cell communications. Lately, these exosomes were proved to have dual faces in cancer. Actually, they can contribute to carcinogenesis through epithelial-mesenchymal transition (EMT), angiogenesis, metastasis and tumor microenvironment (TME) of various cancers, including colorectal cancer (CRC). On the other hand, they can be potential targets for cancer treatment. CRC is one of the most frequent tumors worldwide, with incidence rates rising in the recent decades. In its early stage, CRC is asymptomatic with poor treatment outcomes. Therefore, finding a non-invasive, early diagnostic biomarker tool and/or suitable defender to combat …